{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265705","form_type":"8-K","ticker":"UPB","cik":"0002022626","company_name":"Upstream Bio, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.347327+00:00","generated_at":"2026-05-17T00:26:01.877603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Upstream Bio Q3 loss $33.7M; VIBRANT Ph2 CRSwNP meets primary endpoint","bullets":["VIBRANT Ph2 met primary endpoint: placebo-adjusted NPS reduction of -1.8 (p<0.0001) at 24 weeks.","Key secondary endpoints met: 76% reduction in need for surgery/systemic corticosteroids (p=0.03).","Cash $372.4M as of Sept 30, 2025; expected to fund operations through 2027.","Net loss $33.7M vs $16.0M YoY; R&D expense rose to $33.0M from $15.4M on verekitug costs.","VALIANT Ph2 severe asthma top-line due Q1 2026; VENTURE Ph2 COPD enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265705","json":"https://secwatch.observer/filing/0001193125-25-265705.json","markdown":"https://secwatch.observer/filing/0001193125-25-265705.md","text":"https://secwatch.observer/filing/0001193125-25-265705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022626/000119312525265705/0001193125-25-265705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022626/000119312525265705/upb-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:26:01.877603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}